Eric Lefkofsky and Tempus Getting Big Data to Clinicians

Eric Lefkofsky is a man with a vision and a goal to provide doctors with the data that they need in order to treat cancer more effectively and improve patient outcomes. It is a gap that has been in existence for oncology initiatives and he has founded a startup named Tempus in order to reduce the size of the disjoint in information. It is something that quite a few of the more recent healthcare ventures are aiming to do by using things such as data science and deep learning as just a few of the tools that will merge healthcare and technology in ways not yet seen and read full article.

 

Eric Lefkofsky recently had an interview with Fortune magazine where he explained that there is a need for sources that are able to merge patient genomic information with therapeutic data so that the collaboration can be leveraged in order to reduce the mortality rate in what can often be a devastating problem with fatal consequences. There are many times when clinicians are browsing through data regarding patient results and they may find such things as Herceptin works in only 40% of the patients being monitored. The key Lefkofsky says is being able to determine what those other factors are which are limiting it from being more effective across the spectrum, and Tempus is working to do just that and Eric’s lacrosse camp.

 

The goal is to get a majority of those working in oncology to use the Tempus platform for their data. That will allow the company’s software to get to work aggregating, scrubbing and feeding the clean data back through the system where it should be more useful after having been through all of the transformations which Tempus is able to handle. CRISPR is a reference to a modern gene editing technique that holds potential for treatments of various diseases, and it is one subset of innovation where the Tempus data is needed as soon as possible. Another area which holds extensive potential for being able to collaborate with Tempus technology is that of personalized vaccines. The industry can expect great things from Eric Lefkofsky in the coming years and learn more about Eric.